SEP
ACAD icon

Signature Equity Partners’s Acadia Pharmaceuticals ACAD Stock Holding History

Signature Equity Partners’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$44.6K Sell
1,762
-145
-8% -$3.19K 0.02% 453
2026
Q1 		$42.5K Sell
1,907
-45
-2% -$1.07K 0.02% 451
2025
Q4 		$52.1K Buy
+1,952
New +$46.6K 0.03% 391

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Signature Equity Partners's ACAD Position: Q2 2026 in Review

Signature Equity Partners reduced its Acadia Pharmaceuticals (ACAD) stake by 7.6% in Q2 2026, selling an estimated $3.19K and leaving 1,762 shares worth $44.6K. The position accounts for 0.02% of the portfolio, ranked #453.

Signature Equity Partners first reported a position in ACAD in Q4 2025 and has held it in 3 quarters since. The position peaked at $52.1K in Q4 2025. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Signature Equity Partners held 1,762 shares of Acadia Pharmaceuticals worth $44.6K as of Q2 2026.
  • Signature Equity Partners sold 145 Acadia Pharmaceuticals shares in Q2 2026, an estimated $3.19K.
  • Acadia Pharmaceuticals made up 0.02% of Signature Equity Partners's portfolio in Q2 2026, its #453 holding.
  • Signature Equity Partners first reported a position in Acadia Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Signature Equity Partners's Acadia Pharmaceuticals position peaked at $52.1K in Q4 2025.
  • 354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Signature Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.